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Human leukocyte antigen (HLA) class I allotypes vary in their
ability to present peptides in the absence of tapasin, an essential
component of the peptide loading complex. We quantified tapasin
dependence of all allotypes that are common in European and
African Americans (n = 97), which revealed a broad continuum of
values. Ex vivo examination of cytotoxic T cell responses to the
entire HIV-1 proteome from infected subjects indicates that
tapasin-dependent allotypes present a more limited set of distinct
peptides than do tapasin-independent allotypes, data supported
by computational predictions. This suggests that variation in tapa-
sin dependence may impact the strength of the immune responses
by altering peptide repertoire size. In support of this model, we
observed that individuals carrying HLA class I genotypes charac-
terized by greater tapasin independence progress more slowly to
AIDS and maintain lower viral loads, presumably due to increased
breadth of peptide presentation. Thus, tapasin dependence level,
like HLA zygosity, may serve as a means to restrict or expand
breadth of the HLA-I peptide repertoire across humans, ultimately
influencing immune responses to pathogens and vaccines.
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The classical HLA class I molecules, HLA-A, HLA-B, andHLA-C, present antigenic peptides to CD8+ T cells, eliciting
an adaptive immune response (1). They are generally expressed
on the cell surface as a trimeric complex consisting of HLA class
I heavy chain, β2-microglobulin, and peptide. The genes
encoding heavy chains are highly polymorphic, resulting in ex-
tensive diversity of the peptide repertoire, both within individ-
uals and at the population level. Peptide loading of HLA class I
molecules takes place primarily in the endoplasmic reticulum
within the peptide loading complex (PLC) (2). Tapasin is a
critical component of the PLC, which performs its peptide
“editing” function by association with peptide-empty HLA class
I, stabilizing its structure, and promoting dissociation of low
affinity peptides (3–13).
HLA class I allotypes vary in level of cell surface expression in
the absence of tapasin. Some allotypes are expressed at very low
levels on the surface of tapasin-deficient cells (tapasin-dependent
allotypes), while others exhibit normal expression on these cells
(tapasin-independent allotypes) (14–17). The exact molecular
determinants of tapasin dependence (TD) remain unknown, al-
though amino acids in the peptide binding groove near the peptide
C terminus appear to contribute most to this phenomenon. For
example, a single amino acid change (D116Y) located in this re-
gion distinguishes the highly tapasin-dependent B*44:02 allotype
from the tapasin-independent B*44:05 allotype (17, 18). Previous
data suggest that TD can be defined by the stability of an HLA
class I peptide-free form, where the more stable tapasin-
independent allotypes are capable of selecting peptides for pre-
sentation on their own, while the less stable tapasin-dependent
allotypes require chaperone assistance (6, 8, 14, 19).
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Tapasin function can be targeted by viruses as a means of
downmodulating HLA class I and evading cytotoxic CD8+ T cell
(CTL) responses (20, 21). Similarly, loss of tapasin expression
has been observed in various human cancers (22). Thus, tapasin-
independent HLA class I allotypes may be advantageous in terms
of eliciting CTL responses against virally infected cells or tumor
cells when tapasin function has been diminished. Allotype-specific
regulation of the peptide repertoire by tapasin may also affect the
quality of CTL responses. Here, we quantified the level of TD
across all common HLA allotypes present in European and Af-
rican Americans and tested the functional significance of differ-
ential HLA class I TD and its impact on disease.
Results
TD of Common HLA Class I Allotypes. A panel of 97 distinct lenti-
viral HLA class I expression constructs were generated, in which
HLA heavy chains were fused with a FLAG tag at the N ter-
minus and linked to a ZsGreen reporter via a self-cleaving
peptide for transduction control. The constructs were trans-
duced individually into the human B cell line .220, which does
not express tapasin (23), and into tapasin-reconstituted .220 cells
(.220tpn). There are two common, naturally occurring tapasin
variants, one containing arginine and the other threonine at
position 240 of the mature protein (rs2071888). In order to
evaluate the potential influence of this polymorphism on HLA class
I expression, each variant was transduced separately into .220 cells
with a C-terminal V5 tag. The resulting cell lines stably expressed
tapasin at the same level as assessed by intracellular staining.
HLA class I cell surface expression levels were quantified in
tapasin-deficient and tapasin-sufficient cell lines by flow cytom-
etry using an anti-FLAG mAb (Fig. 1A and SI Appendix, Fig. S1).
This antibody specifically detects transduced allotypes, in con-
trast to W6/32 mAb, a broadly used pan-HLA class I antibody
that can bind endogenous HLA class I, which may be expressed
by .220 cells at low levels. Nevertheless, we observed a strong
correlation between HLA expression levels measured using anti-
FLAG mAb and those determined by staining with W6/32 (SI
Appendix, Fig. S2). This indicated that the FLAG-tagged heavy
chains remained properly folded on the cell surface, since W6/32
only binds β2-microgloblin–associated HLA class I complexes.
Further, allotype-specific HLA class I expression levels in
.220tpn cells were similar to the expression levels in isogenic .221
cells bearing endogenous tapasin, indicating that V5-tagged
tapasin was functioning similarly to the native protein (SI Ap-
pendix, Figs. S1 B and C and S3). Comparison of the flow cyto-
metric data obtained from cells expressing the R240 vs. T240
tapasin variants did not reveal a differential effect of this poly-
morphism on HLA expression levels.
TD values for each allele were generated by calculating the
ratio of expression level in .220tpn cells over expression level in
.220 cells, such that higher scores for a given allotype indicate its
greater dependence on tapasin for cell surface expression
(Fig. 1B and SI Appendix, Table S1). For example, the highly
tapasin-dependent HLA-A*01:02 and HLA-B*44:02 have a ratio
above 100, whereas the highly tapasin-independent HLA-
A*68:01 and HLA-B*35:01 have a ratio of ∼1. TD values across
each HLA class I locus represent a continuum, demonstrating
some level of dependence on tapasin for most allotypes.
Our dataset included 26 of the 27 HLA-B alleles for which
expression levels had been determined previously in the tapasin-
deficient melanoma cell line M553 using W6/32 for cell surface
staining of transfected cells (14). Despite differences in experi-
mental conditions (cell type, DNA delivery, antibody), significant
correlations between the .220 and M553 datasets were observed
for both expression levels in tapasin-deficient cells and fold in-
crease in expression after tapasin reconstitution (SI Appendix,
Fig. S4).
TD Is Associated with Peptide Repertoire Size. The kinetics of
peptide selection may differ between tapasin-independent allo-
types relative to tapasin-dependent allotypes, since peptide se-
lection for tapasin-independent allotypes, which does not require
involvement of the PLC, may proceed faster and with somewhat
greater promiscuity. If so, TD levels of HLA class I allotypes are
likely to influence breadth of the peptide repertoire, i.e., the



















































































































































































































































































































Fig. 1. Tapasin influences HLA class I surface expression. (A) HLA expression levels in .220 cells before and after tapasin reconstitution were measured by flow
cytometry using anti-FLAG mAb. MFI, median fluorescent intensity. Data for tapasin-positive cells represent the average MFI for R240 and T240 tapasin-
expressing cells. (B) TD for each HLA allotype, defined as the ratio of MFI of tapasin-positive over tapasin-negative cells, is shown in log10 scale. Error bars
correspond to SDs calculated from multiple measurements as described in Methods.





















Although multiple factors may influence the immunogenicity of
the presented peptide pool, it stands to reason that a greater
repertoire of peptides present in the HLA peptide binding
groove will generally result in an increased number of immu-
nogenic peptides presented to T cells. Therefore, TD levels may
influence the breadth of CD8+ T cell responses by regulating the
number of peptides bound to HLA class I. To test this hypoth-
esis, we correlated TD levels with breadth of CD8+ T cell re-
sponses against a panel of 410 overlapping synthetic peptides
spanning the HIV-1 proteome in a cohort of 989 HIV-1 clade
C-infected individuals who were genotyped for HLA class I (24).
CD8+ T cell responses from each individual were determined by
an IFN-γ enzyme-linked immunosorbent (ELISpot) assay, and
peptides eliciting a response were tested for association with all
HLA class I alleles present in the cohort. As a result, each HLA
class I allele was assigned a certain number of unique HIV-1
peptides that elicited a CD8+ T cell response. Significant neg-
ative correlations between the level of TD and the number of
peptides associated with each of the HLA-B (r = −0.77, P =
0.0004), HLA-A (r = −0.48, P = 0.04), and HLA-A/B/C allotypes
combined (r = −0.35, P = 0.01) were observed (Fig. 2A and
Table 1). There was no correlation for HLA-C allotypes alone.
Next, we tested for associations between TD score of each
individual and breadth of their corresponding responses
(i.e., number of peptides eliciting a CTL response, regardless of
HLA genotype). A locus-specific TD score for each individual
was calculated as the sum of the TD values for the two alleles at
a given locus, or a “global” TD score was generated by summing
TD values for the four alleles of their HLA-A/B or six alleles of
their HLA-A/B/C genotypes. The global TD score demonstrated
a significant negative correlation with the total number of HIV-1
peptides to which CD8+ T cell responses were detected
(r = −0.24, P = 3 × 10−10, Fig. 2B and Table 1). As in the analysis
of allelic association described above, the HLA-B locus was the
major contributor to this effect (r = −0.24, P = 6 × 10−10,
Table 1).
The correlation between the number of peptides presented
and TD level was further examined using data by Paul et al. (25),
which demonstrated substantial differences in dengue virus
repertoire size for a set of 16 HLA-A and 11 HLA-B allotypes
estimated by peptide binding prediction using the stabilized
matrix method (SMM) (26). This algorithm is trained on in vitro
binding assays, and peptides with predicted affinity (IC50) ≤
500 nM are expected to be presented by the corresponding HLA
class I. Similar to the HIV-1 ELISpot data, the predicted dengue
repertoire size showed a negative correlation with TD of HLA
class I allotypes (Fig. 2C and Table 1), which reached significance
for HLA-B (r = −0.65, P = 0.02), HLA-A (r = −0.46, P = 0.05),
and HLA-A/B allotypes combined (r = −0.53, P = 0.003). The
prediction algorithms NetMHCpan EL 4.0 (27) and SMM appear
to be robust for viral peptidomes, as significant negative correla-
tions were observed between the predicted number of HIV pep-
tides presented by HLA-A/B (using the same overlapping set of
peptides used in the ex vivo analysis in Fig. 2 A and B) and the
corresponding TD scores (r = −0.33, P = 0.003 and r = −0.32, P =
0.03, for NetMHCpan EL 4.0 and SMM, respectively). Of note,
the order of TD scores of four HLA-B alleles, B*57:01, B*27:05,
B*07:02, and B*35:01, corresponds precisely, in a negative man-
ner, to the order of their self-peptide repertoire sizes as estimated
using prediction algorithms (28).
Thus, both ELISpot data and computational prediction algo-
rithms indicate that TD of HLA class I allotypes associates with
more limited peptide repertoires. The negative correlations are
consistent for HLA-A and HLA-B, but not for HLA-C allotypes,
an observation that may be due to the relatively low expression
of HLA-C in general (29) and greater difficulty in measuring and
predicting peptide binding to HLA-C. Notably, the in vitro
binding assays used to build the prediction algorithms do not
involve tapasin. It is possible that tapasin-independent allotypes
bind larger numbers of peptides in these assays due to their
higher stability in a peptide-free form, a characteristic that, in the
ER, liberates their need for tapasin in the peptide loading pro-
cess. This may explain the parallel correlations obtained by both
ex vivo and prediction methods, attesting to the validity of
the latter.
TD Associates with HIV Disease Outcomes. The expansion or re-
striction of the peptide binding repertoire as a function of TD
level may influence disease pathogenesis. To test this, we
assigned TD scores to individuals from two completely inde-
pendent HIV-1 cohorts and interrogated distinct outcomes. Cox
model analysis of 954 antiretroviral therapy-naïve HIV-1 sero-
converters revealed a significant association between higher
global TD and more rapid progression to AIDS as defined by the
CDC in 1987 (AIDS-1987), after adjusting for race and HLA-
B*57/27/35Px alleles (HR = 1.5 per one log10 increase in global
TD score, P = 0.001; Table 2 and Fig. 3A), which are known to
affect AIDS progression in this cohort (30). HLA-B TD provided
the greatest contribution to the global effect, showing a signifi-
cant association on its own (HR = 1.3, P = 0.008). Since there
was no significant effect of TD on progression to CD4 cell
counts <200/μL and AIDS-1993, definitions that precede an
AIDS-defining illness (i.e., AIDS-1987), the detrimental effect of









Fig. 2. Tapasin dependence levels negatively correlate with the number of peptides presented by HLA allotypes. (A) CD8+ T cell responses were measured in
an ELISpot assay in a cohort of HIV-1 infected South Africans. The number of peptides eliciting a CD8+ T cell response associated with each HLA allotype (y
axis) is plotted against the corresponding TD value (x axis). Each dot represents an individual HLA allotype. (B) The total number of peptides to which an
individual elicited responses (y axis) is plotted against the global TD value (x axis) for that individual. The global score equals the sum of six TD values cor-
responding to the HLA-A/B/C genotype. Each dot represents an individual tested in the ELISpot assay. (C) Dengue virus (DENV) repertoire size (y axis), as
predicted using the SMM algorithm for individual HLA-A and HLA-B allotypes (25), is plotted against the corresponding TD values for HLA-A and HLA-B (x
axis). Each dot represents a specific HLA allotype.
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The influence of TD on viral load (VL) was validated in an
independent cohort of 4,306 individuals for whom longitudinal
VL measurements (HIV RNA copies/mL of blood) were avail-
able prior to initiation of antiretroviral therapy. Consistent with
the Cox analysis, TD correlated positively with mean VL (mVL),
where every 1 log10 increase in TD score associated with an in-
crease of 0.21 mean log10 VL (P = 1.2 × 10
−6; Fig. 3B). Analysis
of longitudinal VL in the same set of patients indicated a 0.17
log10 increase in VL over time per 1 log10 increase in TD score
(P = 3 × 10−36; Table 2), mirroring the results observed using
mVL as an outcome. The HLA-A and HLA-B TD scores dem-
onstrated similar effects when analyzed separately (Table 2).
Discussion
HLA class I polymorphism defines multiple allele-specific fea-
tures, including peptide specificity, mRNA/protein expression
levels, and binding to innate immune receptors (31). Here, we
characterize another property that differentiates HLA class I
allotypes, their level of dependence on tapasin to bind and
present peptides on the cell surface. Tapasin-independent allo-
types have greater breadth in HIV peptide presentation to
T cells, making it more difficult for the virus to adapt to these
HLA types, thereby explaining the protective effect of tapasin-
independent HLA class I genotypes (Fig. 3 and Table 1). We
previously reported genetic epidemiological observations indi-
cating an HLA class I heterozygote advantage against HIV (32),
supporting a theory originally put forth by Doherty and Zin-
kernagel proposing that heterozygosity at class I results in a
greater repertoire of viral peptides to which an individual can
respond (33). These studies are further supported by recent
theoretical data (34). Thus, there are at least two mechanisms by
which HLA class I genotypes can enhance the breadth of the
peptide binding repertoire and protect against viral disease:
heterozygosity and tapasin independence.
Tapasin-dependent allotypes require the PLC for peptide load-
ing, and only high affinity peptides are likely to dislodge tapasin
from the peptide binding groove, allowing the HLA–peptide com-
plex to proceed to the cell surface. Tapasin-independent allotypes
do not require the PLC for peptide loading, resulting in greater
promiscuity in the peptides they bind, including peptides that may
often be of low affinity. In support of this model, B*44:02–peptide
complexes were shown to be significantly more thermostable than
B*44:05–peptide complexes, indicating that B*44:02, which strongly
requires tapasin for peptide loading, assembles with higher affinity
peptides than does B*44:05, an allotype that does not require
tapasin for loading peptides (17).
Analogous to the protection against HIV conferred by tapasin-
independent allotypes (i.e., those that bind a greater repertoire
of peptides), greater promiscuity in peptide binding of chicken
major histocompatibility complex (MHC) class I confers strong
protection against Marek’s disease, a highly contagious disease in
this species caused by an alphaherpes virus (35). Along the same
lines, SIV vaccine studies in rhesus monkeys showed that suc-
cessful protection required CTL responses to an exceptionally
broad, low affinity peptide pool restricted by Mamu-E (36).
Taken together, these studies in three distinct species point to
greater breadth of the peptide binding repertoire as a protective
host mechanism against viral disease. This may be of major
consequence in successful vaccine design: Targeting epitopes
restricted by the fastidious tapasin-dependent allotypes is likely
critical for overall success of the vaccine, whereas the more
promiscuous tapasin-independent allotypes may respond effec-
tively to a broader range of vaccine antigens.
Apart from presenting a broader peptide repertoire, tapasin-
independent allotypes would also be relatively beneficial if
tapasin function is affected by the virus, as they would continue
to present viral peptides to CTL. A recent HIV-host interactome
study identified tapasin, among other host proteins, to associate
with HIV-1 Env (37), raising the possibility that this interaction
may impact peptide loading. In general, the ability to load
peptides without being incorporated into the PLC, a character-
istic of tapasin-independent alleles, would be beneficial if any
component of the PLC, including tapasin, is inhibited under
pathological conditions.
We previously reported that tapasin-independent genotypes
associated with faster progression to death after HIV infection
(14), which contrasts with our present findings. The previous
study was premature in this regard, having clear limitations
Table 1. Statistics for Spearman correlation between TD levels and peptide repertoire size corresponding to Fig. 2
HLA-A HLA-B HLA-C HLA-A/B HLA-A/B/C
HIV-1 (allotypes associated CD8+ T cell response) – Fig. 2A n 14 16 13 30 43
r −0.48 −0.77 0.04 −0.57 −0.35
P 0.04 0.0004 0.5 0.0005 0.01
HIV-1 (total CD8+ T cell response) – Fig. 2B n 638 638 638 638 638
r −0.05 −0.24 −0.05 −0.26 −0.24
P 0.09 6 × 10−10 0.1 2 × 10−11 3 × 10−10
DENV (predicted repertoire for individual allotypes) – Fig. 2C n 14 11 25
r −0.46 −0.65 −0.53
P 0.05 0.02 0.003
Bold P values indicate significance (less than or equal to 0.05).
Table 2. Influence of HLA class I TD on progression to AIDS-1987 in seroconverters (n = 954)
and HIV-1 viremia (n = 4.306)
HR per log10 TD increase
† P value VL est. per log10 TD increase
‡ P value
HLA-A/B/C 1.5 0.001 0.17 3 × 10−36
HLA-A 1.2 0.2 0.10 8 × 10−9
HLA-B 1.3 0.008 0.06 4 × 10−12
HLA-C 1.1 0.6 0.10 2 × 10−4
†Cox proportional hazards model adjusted for race and B*57, B*27, B*35-Px allelic effects.
‡Longitudinal VL analysis adjusted for random effects due to each HLA-A, HLA-B, and HLA-C allele present in the
cohort, the time after enrollment, and diploid HLA coding.





















compared to that described herein: 1) smaller sample sizes (n =
496 vs. 954 for survival analyses) and no validation in an inde-
pendent cohort (present study only, n = 4,306); 2) fewer alleles
for which TD values were available (27 HLA-B vs. 97 HLA-A/B/
C alleles); 3) inability to account for global TD levels since only
HLA-B alleles were considered; 4) no functional explanation to
support the genetic data. Overall, the increased power, repro-
ducibility across cohorts, and functional data provided in the
current work convincingly point to the protective effect of
tapasin-independent HLA class I genotypes in HIV disease.
The impact of TD on outcome after HIV infection is clearly
distinct from individual allelic effects, as the most protective
allotype of all, HLA-B*57:01, is highly tapasin-dependent. B*57
allotypes are known to present multiple, highly conserved pro-
tective epitopes (30), an attribute that is rare among HLA al-
lotypes. Rigorous peptide editing within the PLC of B*57 is
likely to be advantageous, as it ensures that the high affinity,
protective epitopes are loaded into the peptide binding groove
and presented on the cell surface. This situation may be re-
stricted to B*57 and perhaps a small set of other allotypes that
present highly protective peptides. For the majority of HLA al-
lotypes, however, enhanced breadth of the peptide repertoire
conferred by tapasin independence favors immune control
of HIV.
The range in breadth of the peptide presentation by distinct
MHC allotypes described herein in humans mirrors that de-
scribed in chicken, where “generalists” and “specialists” have
been identified across class I allotypes (38). In humans, TD
impacts this division (in a continuous manner), whereas in
chicken, the structure of the peptide binding groove determines
which category a specific allotype belongs, an example of con-
vergent evolution. TD of specialists is likely to be protective
against certain diseases, whereas tapasin independence of gen-
eralists protects against others. Thus, natural selection to main-
tain the broad distribution of TD at the population level
contributes to the remarkable plasticity of the immune system in
health and disease.
Methods
Human Subjects. CTL responses were measured in a cohort of 989 individuals
from Durban, South Africa (24). Longitudinal viral load and HLA class I data
were available from a total of 5,114 HIV-1 infected individuals from six US
cohorts and one European cohort: Adult Clinical Trials Group, AIDS Linked to
i.v. Experience (ALIVE), US military HIV Natural History Study, Multicenter
AIDS Cohort Study (MACS), Massachusetts General Hospital Controller Co-
hort, Study on the Consequences of Protease Inhibitor Era, and Swiss HIV
cohort study. Seroconversion time and AIDS progression data were known
for 1,112 patients from the District of Columbia gay cohort study, the
Multicenter Hemophilia Cohort Study, the San Francisco City Clinic Cohort,
MACS, and ALIVE. The representative institutional review boards approved
this study. Each participant approved use of DNA samples for genetic anal-
ysis. All samples provided to us were deidentified.
Cell Lines and Expression Constructs. The human B cell lines .220 and .221 were
generated previously by γ-radiation of 721 cells and do not express HLA-A/B
and may express HLA-C/E/F (16, 39–42). These cell lines were grown in RPMI
1640 medium (Quality Biologicals) supplemented with 10% (vol/vol) fetal
bovine serum (Atlanta Biologicals) and 1× Penicillin-Streptomycin-
L-Glutamine Mixture (Lonza). HEK293T cells used for lentivirus production
were maintained in advanced DMEM (Gibco) supplemented with 10% FBS
and 2 mM L-glutamine (Gibco).
The HLA expression set included common alleles with frequencies >0.5%
in European and African Americans, as well as the following alleles that are
rare or absent in these populations: A*11:02, A*74:03, B*44:05, B*46:01,
B*73:01, and C*18:02. Synthetically derived HLA allele fragments (LifeSct)
were cloned into the modified pLVX-EF1α-IRES-Puro (Clontech) vector (43),
in which EF1α was replaced with the SFFV promoter (pLVX-SFFV-IRES-Puro).
The expression cassette encoded ZsGreen linked via self-cleaved P2A peptide
to HLA with a FLAG-tag inserted between the allele-specific signal peptide
and the mature protein. For tapasin expression, the vector was modified
further by substitution of the puromycin resistance gene with the neomycin
resistance gene (pLVX-SFFV-IRES-Neo). Tapasin was expressed with a V5-tag
at the C terminus. Lentiviral transduction was performed as described in ref.
43. HLA-positive and tapasin-positive cells were selected using 0.25 μg/mL
puromycin and 1 mg/mL G418 (Invivogen), respectively.
Antibodies and Flow Cytometry. Flow cytometric analyses were performed
using the following monoclonal antibodies: APC anti-DYKDDDDK Tag
(anti-FLAG; clone L5; BioLegend), HLA-ABC (W6/32) APC (eBioscience) (44),
anti-V5-Tag Alexa Fluor 647 (clone SV5-Pk1; Bio-Rad). Cell surface staining of
HLA expression was performed on cells grown in 24-well plates in 1 mL of
volume on four different days, with 2-d intervals. For each experiment,
800 μL of cells (105–106) were used for staining, and 200 μL of cells were
cultured further with fresh media. For tapasin detection, cells were fixed and
permeabilized using the BD Cytofix/Cytoperm kit (Beckton Dickinson).
Staining results were acquired using FACSCalibur flow cytometer (Beckton
Dickinson), and analysis was performed using FlowJo software. Estimation of
HLA expression levels involved several adjustments to the obtained APC MFI
A B
Log10 TD































Fig. 3. Tapasin dependence impacts HIV-1 disease. (A) Kaplan–Meyer curves for time to AIDS-1987 are shown for a cohort of ART-naïve HIV-1 seroconverters
equally divided based on their global TD (high, medium, and low, n = 318 in each group). (B) Mean log10VL plotted against log10TD level is shown for a cohort
of ART-naïve HIV-1 patients. Each dot represents the mean log10VL of patient groups divided into increasing bins of 0.1 log10TD. Estimate (est), and P value
were derived by regression analysis adjusted by race.
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values: 1) background MFI of cells transduced with empty vector (i.e., no HLA
insert) were subtracted; 2) MFI values were normalized to the average MFI
across samples to adjust for daily instrumental variation; 3) MFI values were
normalized to the level of ZsGreen to adjust for the level of transduction; 4)
the numerator in the calculation of TD for each allele was the average ex-
pression levels of the corresponding allele in .220tpn cells expressing the
R240 and T240 tapasin variants.
HLA Genotyping and TD Assignment. HLA typing in the HIV-1 cohorts was
performed using a targeted next generation sequencing method. Briefly,
locus-specific primers are used to amplify polymorphic exons of HLA-A, HLA-
B, HLA-C genes with Fluidigm Access Array (Fluidigm). The Fluidigm PCR
amplicons were pooled and subjected to sequencing either on the Roche 454
platform (Roche) or the Illumina MiSeq platform (Illumina). HLA alleles and
genotypes were called using the Omixon HLA Explore (beta version) soft-
ware (Omixon). TD values determined for each HLA allotype are shown in
Fig. 1 and SI Appendix, Table S1. Genotypic TD at each locus for each indi-
vidual were calculated by summing the TD values of the two alleles: TD(HLA-
A) = TD(A1) + TD(A2); TD(HLA-B) = TD(B1) + TD(B2); TD(HLA-C) = TD(C1) +
TD(C2), where A1/A2, B1/B2, and C1/C2 represent the two alleles at HLA-A,
HLA-B, and HLA-C, respectively. The global TD value for each individual was
calculated by summing the TD scores at the three loci: TD(HLA-A/B/C) =
TD(HLA-A) + TD(HLA-B) + TD(HLA-C). We were able to assign TD to 84%
(4,306/5,114) and 86% (954/1,112) of individuals in the longitudinal VL and
seroconverter cohorts, respectively. In the African cohort (ELISpot data),
complete four-digit HLA-A/B/C genotypes were available for 853 individuals,
of which TD scores were assigned to 638 (75%).
HLA Class l Epitope Prediction. Epitope predictions for HIV-1 was performed
by using the SMM (26) and NetMHCpan EL 4.0 (27) algorithms available in
the T cell section of Immune Epitope Database analysis tools (www.IEDB.
org). In both cases, predicted affinity values (IC50 nanomolar) were retrieved
for the specific HLA allele when applicable based on the selected algorithm.
HIV-1 clade C peptides consisted of overlapping 18-mers as previously de-
scribed (24). For prediction purposes, for each 18-mer, all of the possible
9-mers and 10-mers were derived and the lowest IC50 was assigned. The
number of epitopes per HLA allele was calculated for both algorithms based
on the number of peptides predicted to have an IC50 ≤ 500 nM.
Statistics. To identify HLA-peptide associations in the HIV-1 ELISpot assay
(Fig. 2A), we used Fisher’s exact test (forward selection) to identify signifi-
cant (q < 0.05) associations between the recognition of individual peptides
and the expression of particular HLA class I alleles. All HLA class I alleles
expressed at a phenotypic frequency of >3% were included in the analysis.
For disease association, regression analyses were performed in R (v 3.6.0)
using the following packages: lme4 and ggplot2. Analyses of VL was per-
formed using the lmer function. Random effects due to each HLA-A, HLA-B,
and HLA-C allele, the time postenrolment, and a correction for diploid HLA
allele coding were included in the models. We tested two alternative out-
comes: a geometric mean HIV VL (mVL) at all measurement timepoints
(mean log10VL) and the log10 transformed HIV VL at each timepoint. For
survival analyses, we used the coxph function (survival package) and esti-
mated the time to AIDS (CDC 1987 and 1993 definition), CD4+ T cell
count <200 cells/μL, and death.
Correlation tests were performed using GraphPad Prism.
Data Availability. All experimental results described in the paper are pre-
sented in the table and figures. All clinical data underlying the study are
available from the cohorts upon application.
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